Project Grant HT94252510073
Award Date
6/1/25
Completion Date
5/31/28
Dollars Obligated
$1.6M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Houston, TX 77030, USA
Similar Awards
This $1,619,723 federal Project Grant award from the Department of Defense's Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) provides funding to The University of Texas MD Anderson Cancer Center to conduct research targeting novel mediators of breast cancer brain metastasis. The award period runs from April 1, 2024 to March 31, 2027, with the goal of developing new treatments, improving patient care, and advancing scientific understanding in this...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $1,619,668 project grant to The University of Texas MD Anderson Cancer Center to inhibit brain metastases of HER2/neu-positive breast cancers using extracellular vesicles from renovated dendritic cells. The award began on May 1, 2024 and is scheduled for completion on April 30, 2027. The project aims to develop innovative treatments to improve outcomes for military service members and the...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), awarded a $7,001,734 project grant to The University of Texas MD Anderson Cancer Center to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. This 4-year grant, which began on August 15, 2024 and will be completed by August 14, 2028, will support advanced cancer research initiatives at the premier...
The Defense Health Agency awarded a $2,710,479 Project Grant to The University of Texas M.D. Anderson Cancer Center under the Military Medical Research and Development program (CFDA 12.420) to advance the understanding of metastatic breast cancer through the development of a comprehensive research platform. The grant has a performance period from August 15, 2024 to August 14, 2028. The research aims to transform healthcare for military service members and the general public by investigating...
The federal Project Grant award, totaling $505,071.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research by The University of Texas MD Anderson Cancer Center to discover noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The research initiative aims to transform healthcare for military service members and the general public through innovative and impactful cancer...
This federal Project Grant award, totaling $718,858.00 and funded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research conducted by the University of Texas MD Anderson Cancer Center on the discovery of noncanonical antigens in triple-negative breast cancer for the development of novel T cell therapies. The award has a performance period from February 15, 2025, to February 14, 2028, and aims to explore innovative approaches to...
The Defense Health Agency awarded a $735,799 Project Grant to the University of Texas MD Anderson Cancer Center under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant supports the research initiative "INNOVATING BREAST CANCER RNA THERAPY: MECHANISMS AND PHARMACOGENETIC INHIBITORS" with a performance period from November 1, 2024 to October 31, 2027. The objective of this research is to explore innovative approaches to breast cancer prevention,...
This Project Grant award from the Department of the Army Medical Command, under the Military Medical Research and Development federal grant program (CFDA 12.420), supports a $1,559,997.00 research study on a novel blood-brain barrier-permeable agent for treating breast cancer brain metastases. The University of Texas Health Science Center at Houston will conduct this 3-year pharmacology and efficacy study beginning on September 1, 2024. The research aims to explore innovative approaches for...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $1,710,727.00 in funding to Health Research, Inc. (a non-profit organization) to conduct research on targeting the BRSK2 gene in aggressive breast cancer brain metastasis. The award period runs from Sep 30, 2024 to Sep 29, 2027. As a prime grantee, Health Research, Inc. will leverage its expertise in cancer biology, immunotherapy development, and biomarker...
This $3,945,543 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports cancer research and care initiatives at the University of Texas MD Anderson Cancer Center (MD Anderson). The award will fund a 4-year clinical research extension project to advance progress, precision, and equity in breast cancer care. MD Anderson, a leading comprehensive cancer center, will utilize the funding to conduct research activities that...